title: Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer.
abstract: OBJECTIVE
  We investigated the efficacy of maintenance hormone therapy (MHT), which was given to hormone positive metastatic breast cancer (MBC) patients in non-progression status to the previous chemotherapy.
  
  
  METHODS
  This study retrospectively analyzed 76 MBC patients who had been treated with MHT from 2006 to 2010 at a single institute.
  
  
  RESULTS
  For the 76 patients reviewed, the median progression free survival (PFS) to MHT was 14.4 months (95% CI, 11.6-17.3). Prolonged PFS was associated with less previous palliative chemotherapy, fewer metastatic sites, and the absence of visceral metastasis in univariate analysis. Multivariate analysis showed that only the number of previous palliative chemotherapy (HR 1.73, 95% CI, 1.00-2.98; P = 0.04) remained as a significant variable. MHT was generally well tolerated.
  
  
  CONCLUSIONS
  MHT showed considerable efficacy and tolerability in this study. Further randomized prospective study is warranted.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
authors.forename: Seungtaek
authors.initials: S
authors.lastname: Lim
authors.forename: Soohyeon
authors.initials: S
authors.lastname: Lee
authors.forename: Jungwoo
authors.initials: J
authors.lastname: Han
authors.forename: Byeong-Woo
authors.initials: BW
authors.lastname: Park
authors.forename: Seungil
authors.initials: S
authors.lastname: Kim
authors.forename: Seho
authors.initials: S
authors.lastname: Park
authors.forename: Joo-Hang
authors.initials: JH
authors.lastname: Kim
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Choi
authors.forename: Joohyuk
authors.initials: J
authors.lastname: Sohn
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D060046:Maintenance Chemotherapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010166:Palliative Care; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D020845:Selective Estrogen Receptor Modulators
keywords: Breast cancer; ER; Hormone therapy; MBC; MHT; MPA; Maintenance; OS; PFS; PR; RECIST; estrogen receptor; maintenance hormone therapy; medroxyprogesteron acetate; metastatic breast cancer; overall survival; progesterone receptor; progression free survival; response evaluation criteria in solid tumors